Calcium Citrate Absorption Randomized Trial: What the Evidence Says

Quick Answer

Calcium Citrate Absorption Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• A variable degree of carbonation can be seen in stones, and greater carbonate content is associated with culturable microorganisms on the crystal surface, raising the potential need to evaluate for urinary tract infection.Not all laboratories report the presence of carbonated hydroxyapatite or quantify the degree of carbonation. [Tsai Peihsuan (2026); evidence level 3]
• Cohort studies have identified 3 main urinary risk factors associated with CaP stone formation: high urine pH, hypercalciuria, and hypocitraturia. [Tsai Peihsuan (2026); evidence level 3]
• Reduced kidney function in these patients leads to a range of pathological changes in mineral metabolism termed mineral and bone disorder (MBD). [Ilkun Olesya (2026); evidence level 4]
• Indeed, high serum phosphate in patients with ESKD is associated with increased risk of all-cause and cardiovascular (CV) mortality, as well as bone fractures. [Ilkun Olesya (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For calcium citrate absorption randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Tsai Peihsuan (2026). Calcium Phosphate Nephrolithiasis: A Comprehensive Review. DOI: 10.1016/j.xkme.2026.101301. PMCID: PMC13049919. PMID: 41940378. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13049919/
• Ilkun Olesya (2026). Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease. DOI: 10.5527/wjn.v15.i1.114146. PMCID: PMC13010344. PMID: 41884254. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13010344/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.